IBD: Can TNF inhibitors be administered during the third trimester?

Nature Reviews Gastroenterology and Hepatology

Volumn 10, Issue 3, 2013, Pages 130-131

  Nielsen, Ole Haagen ^a   Jess, Tine ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b STATENS SERUM INSTITUT   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; BIOLOGICAL PRODUCT; CERTOLIZUMAB PEGOL; GLUCOCORTICOID; INFLIXIMAB; MERCAPTOPURINE;

DISEASE CONTROL; DRUG EFFECT; DRUG SAFETY; DRUG USE; ENTERITIS; HUMAN; PREGNANCY OUTCOME; PRIORITY JOURNAL; REMISSION; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SHORT SURVEY; THIRD TRIMESTER PREGNANCY; TREATMENT DURATION;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; INFLAMMATORY BOWEL DISEASES; POLYETHYLENE GLYCOLS; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; PREGNANCY TRIMESTER, THIRD; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84875227280     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2012.248     Document Type: Short Survey

References (10)

1. Cornish, J. et al. A meta-Analysis on the influence of inflammatory bowel disease on pregnancy. Gut 56, 830-837 (2007
2. Zelinkova, Z. et al. Effects of discontinuing anti-Tumor necrosis factor therapy during pregnancy on the course of inflammatory bowel disease and neonatal exposure. Clin. Gastroenterol. Hepatol. http://dx.doi.org/10.1016/ j.cgh.2012.10.024
3. Dominitz, J. A., Young, J. C. & Boyko, E. J. Outcomes of infants born to mothers with inflammatory bowel disease: A population-based cohort study. Am. J. Gastroenterol. 97, 641-648 (2002
4. Reddy, D., Murphy, S. J., Kane, S. V., Present, D. H. & Kornbluth, A. A. Relapses of inflammatory bowel disease during pregnancy: In-hospital management and birth outcomes. Am. J. Gastroenterol. 103, 1203-1209 (2008
5. Singh, S., Sedgh, G. & Hussain, R. Unintended pregnancy: Worldwide levels, trends, and outcomes. Stud. Fam. Plann. 41, 241-250 (2010
6. Habal, F. M. & Huang, V. W. Review article: A decision-making algorithm for the management of pregnancy in the inflammatory bowel disease patient. Aliment. Pharmacol. Ther. 35, 501-515 (2012
7. Zelinkova, Z. et al. High intra-uterine exposure to infliximab following maternal anti-TNF treatment during pregnancy. Aliment. Pharmacol. Ther. 33, 1053-1058 (2011
8. Mahadevan, U. et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: Pregnancy and pediatrics. Am. J. Gastroenterol. 106, 214-223 (2011
9. Mahadevan, U. et al. PIANO: A 1000 patient prospective registry of pregnancy outcomes in women with IBD exposed to immunomodulators and biologic therapy [abstract]. Gastroenterology 142 (Suppl. 5), S149 (2012
10. Ben-Horin, S. et al. Detection of infliximab in breast milk of nursing mothers with inflammatory bowel disease. J. Crohns Colitis 5, 555-558 (2011